Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 5 · 71.4%High 0 · 0%

Endothelin receptor antagonists vs placebo

Meters change from baseline in 6MWD · pulmonary arterial hypertension

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 2739 participants
Moderate

Endothelin receptor antagonists vs placebo

Proportion of participants with improved functional class mean duration of study 16.8 weeks · pulmonary arterial hypertension

Endothelin receptor antagonists probably leads to higher proportion of participants with improved functional class mean… compared with placebo (moderate certainty).

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
OR 1.41 [1.16, 1.7]
15 studies · 3060 participants
Moderate

Endothelin receptor antagonists vs placebo

Change from baseline in BDI mean duration of study 14.3 weeks · pulmonary arterial hypertension

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 788 participants
Low

Endothelin receptor antagonists vs placebo

Mortality mean duration of study 30.2 weeks · pulmonary arterial hypertension

Endothelin receptor antagonists showed no clear difference in mortality mean duration of study 30.2 weeks compared with placebo (low certainty).

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
OR 0.78 [0.58, 1.07]
12 studies · 2889 participants
Low

Endothelin receptor antagonists vs placebo

Change from baseline in mean PAP (mmHg) mean duration of study 17.1 weeks · pulmonary arterial hypertension

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 729 participants
Moderate

Endothelin receptor antagonists vs placebo

Change from baseline in PVR (dyn/s/cm5) mean duration of study 15.7 weeks · pulmonary arterial hypertension

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 586 participants
Moderate

Endothelin receptor antagonists vs placebo

Hepatic toxicity mean duration of study 25 weeks · pulmonary arterial hypertension

Endothelin receptor antagonists showed no clear difference in hepatic toxicity mean duration of study 25 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
OR 1.88 [0.91, 3.9]
11 studies · 2250 participants
Moderate